Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768800 | 0.98 | EPHX2 (0.57) | EPHX2GBA1HDAC1L3MBTL1 | |
| SCHEMBL24675920 | 0.94 | EPHX2 (0.67) | EPHX2GBA1HRH4HRH3 | |
| SCHEMBL17776313 | 0.94 | EPHX2 (0.52) | EPHX2GBA1HDAC1 | |
| SCHEMBL22423183 | 0.93 | EPHX2 (0.54) | EPHX2GBA1HDAC1L3MBTL1HRH4 | |
| SCHEMBL18768813 | 0.92 | EPHX2 (0.51) | EPHX2GBA1HDAC1 | |
| SCHEMBL19652938 | 0.92 | EPHX2 (0.56) | EPHX2GBA1HDAC1L3MBTL1HRH4 | |
| SCHEMBL19704892 | 0.91 | EPHX2 (0.52) | EPHX2GBA1HDAC1L3MBTL1HRH4 | |
| SCHEMBL24675933 | 0.91 | EPHX2 (0.52) | EPHX2GBA1HDAC1L3MBTL1HRH4 | |
| SCHEMBL17776310 | 0.90 | EPHX2 (0.54) | EPHX2GBA1HDAC1HRH4HRH3 | |
| SCHEMBL19704885 | 0.88 | EPHX2 (0.48) | EPHX2GBA1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922260-A2 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3666792-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3660041-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660040-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2017205191-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | EPHX2 4126/4885GBA1 3427/4885HDAC1 3548/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | EPHX2 4126/4885GBA1 3427/4885HDAC1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.